福州拓新天成生物科技

Tuoxin Tiancheng is a clinical-stage biotechnology company based in Fuzhou, China, specializing in the development of next-generation T-cell therapies for cancer. The company leverages its proprietary T-MAX platform to engineer CAR-T and TCR-T cells designed to overcome the immunosuppressive microenvironment of solid tumors. Their pipeline includes candidates targeting GPC3 for liver cancer and Claudin 18.2 for gastric and pancreatic cancers. Tuoxin Tiancheng aims to provide curative solutions for patients with refractory or metastatic malignancies through innovative cell engineering and optimized manufacturing processes. The company also maintains robust capabilities in viral vector production and GMP-compliant cell processing to support its clinical programs. Led by experts in gene and cell therapy, the firm is positioned as a key player in the Fujian biotech ecosystem.